<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459055</url>
  </required_header>
  <id_info>
    <org_study_id>ACRO01</org_study_id>
    <nct_id>NCT01459055</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up in Patients Affected With Acrofacial Vitiligo</brief_title>
  <official_title>Long-term Ten Years Follow-up in Patients Affected With Acrofacial Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Irmandade da Santa Casa de Misericordia de Curitiba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Irmandade da Santa Casa de Misericordia de Curitiba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acrofacial vitiligo is a clinical form of vitiligo characterized by macules in distal digits,&#xD;
      periorificial-facial and ano-genital areas. Vitiligo European Task Force classifies vitiligo&#xD;
      as generalized or localized; generalized vitiligo may be further sub-divided into acrofacial,&#xD;
      vulgaris and universalis, and localized vitiligo, into segmental and focal. Some authors do&#xD;
      not believe that acrofacial is a real vitiligo clinical form, considering it as an initial&#xD;
      form of vulgaris vitiligo. The aim of this study is to follow early- diagnosed acrofacial&#xD;
      patients during ten years in order to define if these patients will maintain this clinical&#xD;
      form or will evolute to a more severe clinical form.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vitiligo</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of both genders affected by acrofacial vitiligo diagnosed by one single&#xD;
        dermatologist.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of both genders, aged older than years, able to understand and provide&#xD;
             written informed consent and able to allow compliance at the treatment and the&#xD;
             requirements of the protocol;&#xD;
&#xD;
          2. Presence of acrofacial vitiligo;&#xD;
&#xD;
          3. Able to comprehend and willing to provide written informed consent in accordance with&#xD;
             institutional and regulatory guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1- Subjects assessed as not suitable for the study in the opinion of the investigator&#xD;
&#xD;
        2 -Inability to complete survey&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caio C Silva de Castro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irmandade da Santa Casa de Misericórdia de Curitiba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caio Cesar C Castro, MD, PhD</last_name>
    <phone>00554135682036</phone>
    <email>caio.castro@pucpr.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Curitiba</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80730000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Caio Cesar Silva de Castro, MD, PhD</last_name>
      <phone>00554135682036</phone>
      <email>caio.castro@pucpr.br</email>
    </contact>
    <investigator>
      <last_name>Caio C Silva de Castro, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>October 21, 2011</study_first_submitted>
  <study_first_submitted_qc>October 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Irmandade da Santa Casa de Misericordia de Curitiba</investigator_affiliation>
    <investigator_full_name>Caio Cesar Silva de Castro</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

